At the 2025 ASCO Gastrointestinal Cancers Symposium, researchers reported results from the second primary endpoint of the CheckMate 8HW study, which compared progression-free survival with nivolumab plus ipilimumab vs nivolumab monotherapy across all lines of therapy in patients with microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer.
